{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:00:46Z","timestamp":1790096446847,"version":"4.0.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2008,7,19]],"date-time":"2008-07-19T00:00:00Z","timestamp":1216425600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1007\/s00277-008-0536-2","type":"journal-article","created":{"date-parts":[[2008,7,18]],"date-time":"2008-07-18T13:47:19Z","timestamp":1216388839000},"page":"881-885","source":"Crossref","is-referenced-by-count":31,"title":["Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study"],"prefix":"10.1007","volume":"87","author":[{"given":"Christophe","family":"Ravoet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Mineur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Robin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisette","family":"Debusscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Bosly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Andr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hakim","family":"El Housni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Soree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Bron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Martiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2008,7,19]]},"reference":[{"key":"536_CR1","doi-asserted-by":"crossref","first-page":"4642","DOI":"10.1200\/JCO.2003.04.036","volume":"21","author":"BD Cheson","year":"2003","unstructured":"Cheson BD, Bennet JM, Kopecky KJ, B\u00fcchner T, Willman CL, Estey EH et al (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myelo\u00efd leukaemia. J Clin Oncol 21:4642\u20134649 doi: 10.1200\/JCO.2003.04.036","journal-title":"J Clin Oncol"},{"key":"536_CR2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","volume":"108","author":"BD Cheson","year":"2006","unstructured":"Cheson BD, Greenberg PL, Bennet JM, Lowenberg B, Wijermans PW, Nimer SD et al (2006) Clinical application and proposal for modification of the International working group (IWG) response criteria in myelodysplasia. Blood 108:419\u2013425 doi: 10.1182\/blood-2005-10-4149","journal-title":"Blood"},{"key":"536_CR3","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1200\/JCO.2001.19.4.1167","volume":"19","author":"FA Eskens","year":"2001","unstructured":"Eskens FA, Awada A, cutler DL, de Jonge MJ, Luyten GP, Faber MN, Statkevich P, Sparreboom A, Verweij J, Hanauske AR, Piccart M (2001) Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH66336 given twice daily to patients with advanced solid tumors. J Clin Oncol 19:1167\u20131175","journal-title":"J Clin Oncol"},{"issue":"11","key":"536_CR4","first-page":"421a","volume":"102","author":"EJ Feldman","year":"2003","unstructured":"Feldman EJ, cortes J, Holyoake TL, Simonsson B, De Angelo DJ, lipton JH, Turner AR, Baccarani M, barker J, Guilhot F, Petersdorf S, Silver RT, Wilson JM, Sugrue M, List AF (2003) Continuous oral Lonafarnib (Sarasar\u00e4) for the treatment of patients with myelodysplastic syndrome. Blood 102(11):421a","journal-title":"Blood"},{"key":"536_CR5","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood-2006-07-035725","volume":"109","author":"P Fenaux","year":"2007","unstructured":"Fenaux P, Raza A, Mufti GJ, Aul C, Germing U, Kantarjian G et al (2007) A multicenter phase 2 study of the farnesyltransferase inhibitor tipifarnib in intermediate- to high-risk myelodysplastic syndrome. Blood 109:4158\u20134163 doi: 10.1182\/blood-2006-07-035725","journal-title":"Blood"},{"key":"536_CR6","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/327430a0","volume":"327","author":"H Hirai","year":"1987","unstructured":"Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M et al (1987) A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 327:430\u2013432 doi: 10.1038\/327430a0","journal-title":"Nature"},{"key":"536_CR7","first-page":"1331","volume":"8","author":"S Horiike","year":"1994","unstructured":"Horiike S, Misawa S, Nakai H, Kaneko H, Yokota S, Taniwaki M et al (1994) N-RAS mutation and karyotypic evolution are closely associated with leukemic transformation in myelodysplastic syndrome. Leukemia 8:1331\u20131336","journal-title":"Leukemia"},{"key":"536_CR8","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K et al (2001) Clinical and biologic activity of farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial. Blood 97:3361\u20133369 doi: 10.1182\/blood.V97.11.3361","journal-title":"Blood"},{"key":"536_CR9","doi-asserted-by":"crossref","first-page":"4527","DOI":"10.1182\/blood-2002-11-3359","volume":"102","author":"R Kurzrock","year":"2003","unstructured":"Kurzrock R, Kantarjian HM, Cortes JE, Singhania N, Thomas DA, Wilson EF et al (2003) Farnesyltransferase inhibitor R115777 in myelodysplastic syndrome: clinical and biologic activities in the phase 1 setting. Blood 102:4527\u20134534 doi: 10.1182\/blood-2002-11-3359","journal-title":"Blood"},{"key":"536_CR10","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1200\/JCO.2004.08.082","volume":"22","author":"R Kurzrock","year":"2004","unstructured":"Kurzrock R, Albitar M, Cortes JE, Estey EH, Faderl SH, Garcia-Manero G et al (2004) Phase II study of R115777, a farnesyl transferase inhibitor, in myelodysplastic syndrome. J Clin Oncol 22:1287\u20131292 doi: 10.1200\/JCO.2004.08.082","journal-title":"J Clin Oncol"},{"key":"536_CR11","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2003-02-0633","volume":"102","author":"JE Lancet","year":"2003","unstructured":"Lancet JE, Karp JE (2003) Farnesyltransferase inhibitors in hematologic malignancies: new horizons in therapy. Blood 102:3880\u20133889 doi: 10.1182\/blood-2003-02-0633","journal-title":"Blood"},{"key":"536_CR12","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/330186a0","volume":"330","author":"E Liu","year":"1987","unstructured":"Liu E, Hjelle B, Morgan R, Hecht F, Bishop JM (1987) Mutation of the Kirsten-ras proto-oncogene in human preleukemia. Nature 330:186\u2013188 doi: 10.1038\/330186a0","journal-title":"Nature"},{"key":"536_CR13","first-page":"263","volume":"7","author":"M L\u00fcbbert","year":"1992","unstructured":"L\u00fcbbert M, Mirro J Jr, Kitchingman G, McCormick F, Mertelsmann R, Hermann F et al (1992) Prevalence of N-RAS mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 7:263\u2013268","journal-title":"Oncogene"},{"key":"536_CR14","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1182\/blood.V71.6.1707.1707","volume":"71","author":"J Lyons","year":"1988","unstructured":"Lyons J, Janssen JW, Bartram C, Layton M, Mufti GJ (1988) Mutations of Ki-RAS and N-RAS oncogenes in myelodysplastic syndromes. Blood 71:1707\u20131712","journal-title":"Blood"},{"key":"536_CR15","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/sj.leu.2401044","volume":"12","author":"RA Padua","year":"1998","unstructured":"Padua RA, Guinn BA, Al-Sabah AI, Smith M, Taylor C, Pettersson T et al (1998) RAS, FMS and p53 mutations and poor clinical outcome in myelodysplasias: a 10-year follow-up. Leukemia 12:887\u2013892 doi: 10.1038\/sj.leu.2401044","journal-title":"Leukemia"},{"key":"536_CR16","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1182\/blood.V82.2.590.590","volume":"82","author":"RL Paquette","year":"1993","unstructured":"Paquette RL, Landaw EM, Pierre RV, Kahan J, L\u00fcbbert M, Lazcano O et al (1993) N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 82:590\u2013599","journal-title":"Blood"},{"issue":"11","key":"536_CR17","doi-asserted-by":"crossref","first-page":"133a","DOI":"10.1182\/blood.V104.11.133.133","volume":"104","author":"T Raz","year":"2004","unstructured":"Raz T, Mohammad A, Daley GQ (2004) Resistance to the farnesyl transferase inhibitor SCH66336\/Lonafarnib caused by mutations in the target protein farnesyl transferase beta. Blood 104(11):133a","journal-title":"Blood"},{"key":"536_CR18","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1182\/blood.V96.5.1655","volume":"96","author":"CWM Reuter","year":"2000","unstructured":"Reuter CWM, Morgan MA, Bergmann L (2000) Targeting the Ras signalling pathway: a rational, mechanism-based treatment for hematologic malignancies. Blood 96:1655\u20131669","journal-title":"Blood"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0536-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-008-0536-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-008-0536-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T03:16:18Z","timestamp":1588821378000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-008-0536-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7,19]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["536"],"URL":"https:\/\/doi.org\/10.1007\/s00277-008-0536-2","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,7,19]]}}}